Everything is favorable for DcVaxL: WHO redefinition of GBM is the best; UK/Germany trial registry update reflecting the new 6 Endpoints is the bestest. About to come prior to the pub is the US registry update I bet. 2018 JTM paper blended data is still the sample of what is about to come out in terms of efficacy. Acting FDA Commish Janet Woodcock has just given a presentation on how best they are accelerating immunotherapy approvals that she could only talk about CAR-T but it is her way of telling how fast they will approve DcVaxL when we file one BLA or already in I don't know, imo. The PPS is going to go thru the roof as everything is favorable as we speak!
News 
Market Data 
Discover 
